What sector does TransMedics Group, Inc. belong to?

TransMedics Group, Inc. operates in the Health Care sector, specifically the Health Care Equipment industry, and is listed on the US markets.

What is the current share price of TMDX?

As of the latest available quote, TMDX traded at $82.18. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of TMDX?

TransMedics Group, Inc. has a price-to-earnings (P/E) ratio of about 21.29. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of TMDX?

The market capitalisation of TransMedics Group, Inc. is approximately $3.21B.

Is TransMedics Group, Inc. profitable?

For its latest reported financial year, TransMedics Group, Inc. recorded a net profit margin of about 31.43%.

Does TMDX pay a dividend?

TransMedics Group, Inc. does not currently show a dividend yield in our data.

What is the return on equity (ROE) of TMDX?

TransMedics Group, Inc. has a return on equity (ROE) of about 36.73%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of TMDX?

Over the past 52 weeks, TMDX has traded between a low of $60.11 and a high of $156.00.

TransMedics Group, Inc.

TMDX US Health Care Health Care Equipment

S&P 600

$82.18

-3.36%

Delayed · cached 15 min

Fair value analysis

TMDX

TransMedics Group, Inc.

$82.18

Close used for this calculation

$74.49Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

78/100

Profitability25/25

Returns13/25

Balance Sheet25/25

Efficiency15/25

Growth12/25

Strong

Quality radar

Consensus fair value

$74.49

Near FV

▼ -9.4% against the close used

Model range $37.34 – $146.10

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$37.34Fair value$74.49Bull$146.10

FairClose

52-week traded range

52W low $62.0452W high $150.42

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

TransMedics Group, Inc. closed at $82.18, 10.3% above the consensus fair value of $74.49 drawn from 8 valuation models.

Financial DNA score 78/100 — Strong. P/E of 16.9x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$67.86

-17.4%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

$37.34

-54.6%

√(22.5 × EPS × BVPS)

EPS=4.87, BVPS=12.72 · outside Graham range (P/E 16.9, P/B 6.5) — asset-light, treat as a rough floor

P/E Fair Value

$97.40

+18.5%

EPS × 20x (sector P/E)

EPS=4.87, Sector P/E=20x

Peter Lynch (PEG)

$146.10

+77.8%

EPS × Growth% (PEG = 1 is fair)

EPS=4.87, g=30%

EV/EBITDA

$62.54

-23.9%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=135.77M

Book Value (P/B)

$97.73

+18.9%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=12.72, ROE=36.7%, g=6%, r=10%

Reverse DCF

$82.18

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 4.9% | Historical: 40%

Margin of Safety

$50.65

-38.4%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=67.53, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer